SAN RAMON, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET.
The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies (“Cooper”) has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$95.68 |
Daily Change: | 0.50 0.53 |
Daily Volume: | 788,686 |
Market Cap: | US$19.100B |
December 17, 2024 December 05, 2024 September 03, 2024 August 28, 2024 August 01, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load